We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Company Profile: GeneNews Limited: bringing the blood transcriptome to personalized medicine

    David J Novak

    * Author for correspondence

    GeneNews Ltd, 2–2 East Beaver Creek Road, Richmond Hill, Ontario, L4B 2N3, Canada.

    ,
    Gailina J Liew

    GeneNews Ltd, 2–2 East Beaver Creek Road, Richmond Hill, Ontario, L4B 2N3, Canada

    &
    Choong-Chin Liew

    GeneNews Ltd, 2–2 East Beaver Creek Road, Richmond Hill, Ontario, L4B 2N3, Canada

    Published Online:https://doi.org/10.2217/pgs.12.12

    GeneNews Limited (TSX:GEN) is a molecular diagnostics company, uniquely positioned to deliver on the promise of personalized medicine. GeneNews has developed and patented the Sentinel Principle®, an innovative approach to identify clinically actionable disease biomarkers from the blood transcriptome. Novel biomarker panels have been identified to address unmet clinical needs in a broad spectrum of malignancy, including those for oncology, cardiovascular, metabolic and neurological related disorders. Currently available products and services from GeneNews are: ColonSentry™, the world’s first blood-based molecular test for colorectal cancer, and; the SentinelGX™ Pharmacogenomic and Companion Diagnostic BloodRNA™ services, established to effectively support pharmaceutical partners in their companion diagnostic, development efforts.

    References

    • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin.62(1),10–29 (2012).
    • Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology112(2),594–642 (1997).
    • Subramanian S, Bobashev G, Morris RJ. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol. Biomarkers Prev.18(7),1971–1978 (2009).
    • Sewitch MJ, Fournier C, Ciampi A, Dyachenko A. Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol.7,39 (2007).